A new study found that starting patients on a lower dose of enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) can improve tolerability without reducing survival in advanced urothelial carcinoma.
Researchers analyzed data from 496 patients treated with this first-line combination and compared standard dosing with lower starting doses. Patients who began at a reduced dose had fewer treatment interruptions, while overall survival was similar between both groups.
The benefit was especially clear in older and less physically fit patients, who tolerated treatment better without losing effectiveness. These findings suggest that adjusting the starting dose may help patients stay on therapy longer and improve quality of life without compromising outcomes.